We are living in a golden age of immunotherapy. By engaging the immune system to overcome diseases and disorders, medicines are more targeted and efficacious than ever before. As an industry, we are finally making strides in solving some of the most difficult medical challenges that patients face.
However, certain hurdles have barred the immunotherapy field from fully addressing the unmet needs of patients. Engaging the immune system and T cells to fight disease can lead to systemic toxicity caused by cytokine release and deadly inflammation. This high toxicity profile prevents immunotherapies from being combined with other medicines, making them less-than-ideal candidates for treating different diseases—including solid tumors, which require a multi-faceted approach.
In order to truly address unmet medical needs in cancer, autoimmune disorders and infectious diseases, we are focused on developing highly efficacious and durable immunotherapies with improved safety profiles. Currently, we have multiple biotherapeutic antibodies in clinical and preclinical development for treatment of multiple myeloma, lymphoma and prostate cancer to help address unmet patient needs.